[1]
|
Redlich CA, Sparer J, Cullen MR. Sick-building syndrome. Lancet, 1997; 349, 1013-6 doi: 10.1016/S0140-6736(96)07220-0 |
[2]
|
Menzies D, Bourbeau J. Building-related illnesses. N Engl J Med, 1997; 337, 1524-31. doi: 10.1056/NEJM199711203372107 |
[3]
|
Hodgson M. Sick building syndrome. Occup Med, 2000; 15, 571-85. |
[4]
|
Norbäck D, Edling C. Environmental, occupational, and personal factors related to the prevalence of sick building syndrome in the general population. Br J Ind Med, 1991; 48, 451-62. http://europepmc.org/abstract/MED/1854648 |
[5]
|
Matsuzaka Y, Ohkubo T, Kikuti YY, et al. Association of sick building syndrome with neuropathy target esterase (NTE) activity in Japanese. Environ Toxicol, 2014; 29, 1217-26. doi: 10.1002/tox.v29.10 |
[6]
|
Matsuzaka Y, Kikuti YY, Mizutani A, et al. Association study between sick building syndrome and polymorphisms of seven human detoxification genes in the Japanese. Environ Toxicol Pharmacol, 2010; 29, 190-4. doi: 10.1016/j.etap.2009.11.007 |
[7]
|
Norbäck D. An update on sick building syndrome. Curr Opin Allergy Clin Immunol, 2009; 9, 55-9. doi: 10.1097/ACI.0b013e32831f8f08 |
[8]
|
Burge PS. Sick building syndrome. Occup Environ Med, 2004; 61, 185-90. doi: 10.1136/oem.2003.008813 |
[9]
|
Straus DC. Molds, mycotoxins, and sick building syndrome. Toxicol Ind Health, 2009; 25, 617-35. doi: 10.1177/0748233709348287 |
[10]
|
Jacobs RL, Andrews CP, Coalson JJ. Hypersensitivity pneumonitis:beyond classic occupational disease-changing concepts of diagnosis and management. Ann Allergy Asthma Immunol, 2005; 95, 115-28. doi: 10.1016/S1081-1206(10)61200-8 |
[11]
|
Patel AM, Ryu JH, Reed CE. Hypersensitivity pneumonitis:current concepts and future questions. J Allergy Clin Immunol, 2001; 108, 661-70. doi: 10.1067/mai.2001.119570 |
[12]
|
Obayashi K, Saeki K, Kurumatani N. Independent Associations Between Nocturia and Nighttime Blood Pressure/Dipping in Elderly Individuals:The HEIJO-KYO Cohort. J Am Geriatr Soc, 2015; 63, 733-8. doi: 10.1111/jgs.2015.63.issue-4 |
[13]
|
Saeki K, Obayashi K, Tone N, et al. A warmer indoor environment in the evening and shorter sleep onset latency in winter:The HEIJO-KYO study. Physiol Behav, 2015; 149, 29-34. doi: 10.1016/j.physbeh.2015.05.022 |
[14]
|
Saeki K, Obayashi K, Tone N, et al. Daytime cold exposure and salt intake based on nocturnal urinary sodium excretion:A cross-sectional analysis of the HEIJO-KYO study. Physiol Behav, 2015; 152, 300-6. doi: 10.1016/j.physbeh.2015.10.015 |
[15]
|
Takahashi K, Otsuki T, Mase A, et al. Negatively-charged air conditions and responses of the human psycho-neuroendocrino-immune network. Environ Int, 2008; 34, 765-72. doi: 10.1016/j.envint.2008.01.003 |
[16]
|
Takahashi K, Otsuki T, Mase A, et al. Two weeks of permanence in negatively-charged air conditions causes alteration of natural killer cell function. Int J Immunopathol Pharmacol, 2009; 22, 333-42. doi: 10.1177/039463200902200210 |
[17]
|
Nishimura Y, Takahashi K, Mase A, et al. Exposure to negatively charged-particle dominant air-conditions on human lymphocytes in vitro activates immunological responses. Immunobiology, 2015; 220, 1359-68. doi: 10.1016/j.imbio.2015.07.006 |
[18]
|
Nishimura Y, Takahashi K, Mase A, et al. Enhancement of NK Cell Cytotoxicity Induced by Long-Term Living in Negatively Charged-Particle Dominant Indoor Air-Conditions. PLoS One, 2015; 10, e0132373. doi: 10.1371/journal.pone.0132373 |
[19]
|
Wolf G. Insulin resistance and obesity:resistin, a hormone secreted by adipose tissue. Nutr Rev, 2004; 62, 389-94. doi: 10.1111/nure.2004.62.issue-10 |
[20]
|
Haluzik M, Haluzikova D. The role of resistin in obesity-induced insulin resistance. Curr Opin Investig Drugs, 2006; 7, 306-11. https://www.researchgate.net/publication/7154333_The_role_of_resistin_in_obesity-induced_insulin_resistance |
[21]
|
Filková M, Haluzík M, Gay S, et al. The role of resistin as a regulator of inflammation:Implications for various human pathologies. Clin Immunol, 2009; 133, 157-70. doi: 10.1016/j.clim.2009.07.013 |
[22]
|
Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett, 1992; 307, 97-101. doi: 10.1016/0014-5793(92)80909-Z |
[23]
|
Kunkel SL, Lukacs NW, Strieter RM. The role of interleukin-8 in the infectious process. Ann N Y Acad Sci, 1994; 730, 134-43. doi: 10.1111/nyas.1994.730.issue-1 |
[24]
|
Roebuck KA. Oxidant stress regulation of IL-8 and ICAM-1 gene expression:differential activation and binding of the transcription factors AP-1 and NF-κB. Int J Mol Med, 1999; 4, 223-30. http://www.ncbi.nlm.nih.gov/pubmed/10425270 |
[25]
|
Jain SK, Rains J, Croad J, et al. Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-alpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid Redox Signal, 2009; 11, 241-9. doi: 10.1089/ars.2008.2140 |
[26]
|
Ivison SM, Wang C, Himmel ME, et al. Oxidative stress enhances IL-8 and inhibits CCL20 production from intestinal epithelial cells in response to bacterial flagellin. Am J Physiol Gastrointest Liver Physiol, 2010; 299, G733-41. doi: 10.1152/ajpgi.00089.2010 |
[27]
|
Paszti-Gere E, Csibrik-Nemeth E, Szeker K, et al. Acute oxidative stress affects IL-8 and TNF-α expression in IPEC-J2 porcine epithelial cells. Inflammation, 2012; 35, 994-1004. doi: 10.1007/s10753-011-9403-8 |
[28]
|
Benditt EP, Hoffman JS, Eriksen N, et al. SAA, an apoprotein of HDL:its structure and function. Ann N Y Acad Sci, 1982; 389, 183-9. doi: 10.1111/nyas.1982.389.issue-1 |
[29]
|
Salazar A, Pintó X, Mañá J. Serum amyloid A and high-density lipoprotein cholesterol:serum markers of inflammation in sarcoidosis and other systemic disorders. Eur J Clin Invest, 2001; 31, 1070-7. doi: 10.1046/j.1365-2362.2001.00913.x |
[30]
|
Hua S, Song C, Geczy CL, et al. A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep, 2009; 14, 187-96. doi: 10.1179/135100009X12525712409490 |
[31]
|
Malle E, Steinmetz A, Raynes JG. Serum amyloid A (SAA):an acute phase protein and apolipoprotein. Atherosclerosis, 1993; 102, 131-46. doi: 10.1016/0021-9150(93)90155-N |
[32]
|
Marhaug G, Dowton SB. Serum amyloid A:an acute phase apolipoprotein and precursor of AA amyloid. Baillieres Clin Rheumatol, 1994; 8, 553-73. doi: 10.1016/S0950-3579(05)80115-3 |
[33]
|
Malle E, De Beer FC. Human serum amyloid A (SAA) protein:a prominent acute-phase reactant for clinical practice. Eur J Clin Invest, 1996; 26, 427-35. doi: 10.1046/j.1365-2362.1996.159291.x |
[34]
|
Willcox BJ, Abbott RD, Yano K, et al. C-reactive protein, cardiovascular disease and stroke:new roles for an old biomarker. Expert Rev Neurother, 2004; 4, 507-18. doi: 10.1586/14737175.4.3.507 |
[35]
|
Di Napoli M, Schwaninger M, Cappelli R, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke:a statement for health care professionals from the CRP Pooling Project members. Stroke, 2005; 36, 1316-29. doi: 10.1161/01.STR.0000165929.78756.ed |
[36]
|
Clearfield MB. C-reactive protein:a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc, 2005; 105, 409-16. http://www.citeulike.org/group/982/article/697790 |
[37]
|
Yeh ET. High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Clin Cardiol, 2005; 28, 408-12. doi: 10.1002/clc.v28:9 |